Denali Therapeutics Inc (DNLI) - Total Liabilities

Latest as of June 2026: $322.78 Million USD

Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has total liabilities worth $322.78 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Denali Therapeutics Inc (DNLI) long-term investment share to see how much of total assets are deployed in long-term investments.

Denali Therapeutics Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how Denali Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see DNLI total asset value.

Denali Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Denali Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	China	CN¥1.17 Billion
First Financial Bancorp NASDAQ:FFBC	USA	$18.36 Billion
Universal Microwave Technology TWO:3491	Taiwan	NT$2.24 Billion
Hiab B HE:HIAB	Finland	€618.20 Million
Guangzhou Development Group Inc SHG:600098	China	CN¥53.26 Billion
ACERINOX ADR 1/2/EO-25 F:ACE	Germany	€3.52 Billion
EQB Inc. TO:EQB	Canada	CA$48.97 Billion
Tofas Turk Otomobil Fabrikasi AS IS:TOASO	Turkey	TL150.07 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Denali Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Denali Therapeutics Inc (DNLI) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	8.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Denali Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Denali Therapeutics Inc (2015–2025)

The table below shows the annual total liabilities of Denali Therapeutics Inc from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	$131.09 Million	-9.28%
2024-12-31	$144.50 Million	+17.51%
2023-12-31	$122.96 Million	-70.57%
2022-12-31	$417.81 Million	-5.44%
2021-12-31	$441.87 Million	-2.62%
2020-12-31	$453.75 Million	+186.56%
2019-12-31	$158.34 Million	+37.52%
2018-12-31	$115.14 Million	+450.25%
2017-12-31	$20.93 Million	+26.45%
2016-12-31	$16.55 Million	-68.37%
2015-12-31	$52.32 Million	--

About Denali Therapeutics Inc

NASDAQ:DNLI USA Biotechnology

Market Cap

$3.22 Billion

Market Cap Rank

#4724 Global

#1606 in USA

Share Price

$20.13

Change (1 day)

+0.35%

52-Week Range

$12.75 - $27.21

All Time High

$93.56